Walid M. Awni,Tolga Baykal,Barry M. Bernstein,Scott c. Brun,Daniel E. Cohen,Emily O. Dumas,Sandeep Dutta,Amit Khatri,Cheri E. Klein,Rajeev M. Menon,Sven Mensing,Thomas J. Podsadecki,Lino X Rodrigues J
申请号：
US15738762
公开号：
US20180177778A1
申请日:
2016.06.28
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The present invention features interferon-free therapies for treating Hepatitis C Virus (HCV) genotypes 1b, 2, 3 or 4. In one aspect, the therapies comprises administering Compound 1 (Paritaprevir), Ritonavir, and Compound 2 (Ombitasvir) to a subject infected with HCV genotype 1b or 4, wherein the therapies do not include the administration of any interferon, and the therapies last from 8 to 12 weeks. Preferably, the therapies do not include the administration of any ribavirin.
